<?xml version="1.0" ?>
<document id="4d94a96a67f554bab5caafc4501fb7fda538609f">
  <chunk id="4d94a96a67f554bab5caafc4501fb7fda538609f.c0" text="molecules Anti-Herpetic, Anti-Dengue and Antineoplastic Activities of Simple and Heterocycle-Fused Derivatives of Terpenyl-1,4-Naphthoquinone and 1,4-Anthraquinone †">
    <entity charOffset="0-9" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c0.e0" ontology_id="CHEBI_25367" text="molecules" type="chemical"/>
    <entity charOffset="41-55" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c0.e1" ontology_id="CHEBI_35610" text="Antineoplastic" type="chemical"/>
  </chunk>
  <chunk id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1" text="Quinones are secondary metabolites of higher plants associated with many biological activities, including antiviral effects and cytotoxicity. In this study, the anti-herpetic and anti-dengue evaluation of 27 terpenyl-1,4-naphthoquinone (NQ), 1,4-anthraquinone (AQ) and heterocycle-fused quinone (HetQ) derivatives was done in vitro against Human Herpesvirus (HHV) type 1 and 2, and Dengue virus serotype 2 (DENV-2). The cytotoxicity on HeLa and Jurkat tumor cell lines was also tested. Using plaque forming unit assays, cell viability assays and molecular docking, we found that NQ 4 was the best antiviral compound, while AQ 11 was the most active and selective molecule on the tested tumor cells. NQ 4 showed a fair antiviral activity against Herpesviruses (EC 50 : &lt;0.4 µg/mL, &lt;1.28 µM) and DENV-2 (1.6 µg/mL, 5.1 µM) on pre-infective stages. Additionally, NQ 4 disrupted the viral attachment of HHV-1 to Vero cells (EC 50 : 0.12 µg/mL, 0.38 µM) with a very high selectivity index (SI = 1728). The in silico analysis predicted that this quinone could bind to the prefusion form of the E glycoprotein of DENV-2. These findings demonstrate that NQ 4 is a potent and highly selective antiviral compound, while suggesting its ability to prevent Herpes and Dengue infections. Additionally, AQ 11 can be considered of interest as a leader for the design of new anticancer agents.">
    <entity charOffset="0-8" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e0" ontology_id="CHEBI_36141" text="Quinones" type="chemical"/>
    <entity charOffset="13-34" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e1" ontology_id="CHEBI_25212" text="secondary metabolites" type="chemical"/>
    <entity charOffset="23-34" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e2" ontology_id="CHEBI_25212" text="metabolites" type="chemical"/>
    <entity charOffset="106-115" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e3" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="287-294" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e4" ontology_id="CHEBI_16509" text="quinone" type="chemical"/>
    <entity charOffset="287-294" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e5" ontology_id="CHEBI_36141" text="quinone" type="chemical"/>
    <entity charOffset="597-606" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e6" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="663-671" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e7" ontology_id="CHEBI_25367" text="molecule" type="chemical"/>
    <entity charOffset="718-727" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e8" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="1040-1047" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e9" ontology_id="CHEBI_16509" text="quinone" type="chemical"/>
    <entity charOffset="1040-1047" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e10" ontology_id="CHEBI_36141" text="quinone" type="chemical"/>
    <entity charOffset="1090-1102" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e11" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="1184-1193" id="4d94a96a67f554bab5caafc4501fb7fda538609f.c1.e12" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
  </chunk>
</document>
